Cargando…
Construction of VSVΔ51M oncolytic virus expressing human interleukin-12
The use of oncolytic viruses (OVs) in combination with cytokines, such as IL-12, is a promising approach for cancer treatment that addresses the limitations of current standard treatments and traditional cancer immunotherapies. IL-12, a proinflammatory cytokine, triggers intracellular signaling path...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225647/ https://www.ncbi.nlm.nih.gov/pubmed/37255540 http://dx.doi.org/10.3389/fmolb.2023.1190669 |
_version_ | 1785050420286062592 |
---|---|
author | Abdulal, Rwaa H. Malki, Jana S. Ghazal, Ezdehar Alsaieedi, Ahdab A. Almahboub, Sarah A. Khan, Muhammad Yasir Alsulaiman, Reem M. Ghaith, Mazen M. Abujamel, Turki S. Ganash, Magdah Mahmoud, Ahmad Bakur Alkayyal, Almohanad A. Hashem, Anwar M. |
author_facet | Abdulal, Rwaa H. Malki, Jana S. Ghazal, Ezdehar Alsaieedi, Ahdab A. Almahboub, Sarah A. Khan, Muhammad Yasir Alsulaiman, Reem M. Ghaith, Mazen M. Abujamel, Turki S. Ganash, Magdah Mahmoud, Ahmad Bakur Alkayyal, Almohanad A. Hashem, Anwar M. |
author_sort | Abdulal, Rwaa H. |
collection | PubMed |
description | The use of oncolytic viruses (OVs) in combination with cytokines, such as IL-12, is a promising approach for cancer treatment that addresses the limitations of current standard treatments and traditional cancer immunotherapies. IL-12, a proinflammatory cytokine, triggers intracellular signaling pathways that lead to increased apoptosis of tumor cells and enhanced antitumor activity of immune cells via IFN-γ induction, making this cytokine a promising candidate for cancer therapy. Targeted expression of IL-12 within tumors has been shown to play a crucial role in tumor eradication. The recent development of oncolytic viruses enables targeted delivery and expression of IL-12 at the tumor site, thereby addressing the systemic toxicities associated with traditional cancer therapy. In this study, we constructed an oncolytic virus, VSVΔ51M, based on the commercially available VSV wild-type backbone and further modified it to express human IL-12. Our preclinical data confirmed the safety and limited toxicity of the modified virus, VSV-Δ51M-hIL-12, supporting its potential use for clinical development. |
format | Online Article Text |
id | pubmed-10225647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102256472023-05-30 Construction of VSVΔ51M oncolytic virus expressing human interleukin-12 Abdulal, Rwaa H. Malki, Jana S. Ghazal, Ezdehar Alsaieedi, Ahdab A. Almahboub, Sarah A. Khan, Muhammad Yasir Alsulaiman, Reem M. Ghaith, Mazen M. Abujamel, Turki S. Ganash, Magdah Mahmoud, Ahmad Bakur Alkayyal, Almohanad A. Hashem, Anwar M. Front Mol Biosci Molecular Biosciences The use of oncolytic viruses (OVs) in combination with cytokines, such as IL-12, is a promising approach for cancer treatment that addresses the limitations of current standard treatments and traditional cancer immunotherapies. IL-12, a proinflammatory cytokine, triggers intracellular signaling pathways that lead to increased apoptosis of tumor cells and enhanced antitumor activity of immune cells via IFN-γ induction, making this cytokine a promising candidate for cancer therapy. Targeted expression of IL-12 within tumors has been shown to play a crucial role in tumor eradication. The recent development of oncolytic viruses enables targeted delivery and expression of IL-12 at the tumor site, thereby addressing the systemic toxicities associated with traditional cancer therapy. In this study, we constructed an oncolytic virus, VSVΔ51M, based on the commercially available VSV wild-type backbone and further modified it to express human IL-12. Our preclinical data confirmed the safety and limited toxicity of the modified virus, VSV-Δ51M-hIL-12, supporting its potential use for clinical development. Frontiers Media S.A. 2023-05-15 /pmc/articles/PMC10225647/ /pubmed/37255540 http://dx.doi.org/10.3389/fmolb.2023.1190669 Text en Copyright © 2023 Abdulal, Malki, Ghazal, Alsaieedi, Almahboub, Khan, Alsulaiman, Ghaith, Abujamel, Ganash, Mahmoud, Alkayyal and Hashem. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Molecular Biosciences Abdulal, Rwaa H. Malki, Jana S. Ghazal, Ezdehar Alsaieedi, Ahdab A. Almahboub, Sarah A. Khan, Muhammad Yasir Alsulaiman, Reem M. Ghaith, Mazen M. Abujamel, Turki S. Ganash, Magdah Mahmoud, Ahmad Bakur Alkayyal, Almohanad A. Hashem, Anwar M. Construction of VSVΔ51M oncolytic virus expressing human interleukin-12 |
title | Construction of VSVΔ51M oncolytic virus expressing human interleukin-12 |
title_full | Construction of VSVΔ51M oncolytic virus expressing human interleukin-12 |
title_fullStr | Construction of VSVΔ51M oncolytic virus expressing human interleukin-12 |
title_full_unstemmed | Construction of VSVΔ51M oncolytic virus expressing human interleukin-12 |
title_short | Construction of VSVΔ51M oncolytic virus expressing human interleukin-12 |
title_sort | construction of vsvδ51m oncolytic virus expressing human interleukin-12 |
topic | Molecular Biosciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225647/ https://www.ncbi.nlm.nih.gov/pubmed/37255540 http://dx.doi.org/10.3389/fmolb.2023.1190669 |
work_keys_str_mv | AT abdulalrwaah constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT malkijanas constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT ghazalezdehar constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT alsaieediahdaba constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT almahboubsaraha constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT khanmuhammadyasir constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT alsulaimanreemm constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT ghaithmazenm constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT abujamelturkis constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT ganashmagdah constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT mahmoudahmadbakur constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT alkayyalalmohanada constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 AT hashemanwarm constructionofvsvd51moncolyticvirusexpressinghumaninterleukin12 |